Solid Biosciences (NASDAQ: SLDB) CMO awarded 58,847 RSUs on milestone

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Brooks Gabriel reported acquisition or exercise transactions in this Form 4 filing.

Solid Biosciences Inc. Chief Medical Officer Brooks Gabriel reported an award of 58,847 restricted stock units (RSUs) tied to performance stock units. Each RSU represents a right to receive one share of common stock as it vests. These RSUs relate to the second of four performance milestones under PSUs originally granted on June 11, 2024.

The Board determined that the performance criteria for the second milestone were met on January 29, 2026. The associated RSUs will vest only if Gabriel continues to serve the company through the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

Insider Trade Summary 10b5-1

1 transaction reported

Mixed 1 txn

Insider Brooks Gabriel

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	58,847	$0.00	--

Holdings After Transaction: Restricted Stock Units — 58,847 shares (Direct, null)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

Key Figures

RSUs awarded: 58,847 RSUs PSU grant date: June 11, 2024 Milestone proportion: 25% per milestone +3 more

6 metrics

RSUs awarded 58,847 RSUs Grant/award acquisition reported on January 29, 2026

PSU grant date June 11, 2024 Original performance stock units grant underlying the RSUs

Milestone proportion 25% per milestone Each of four independent performance milestones covers 25% of target RSUs

Milestones count 4 milestones Independent performance milestones predetermined by the Board

Milestone 2 certification date January 29, 2026 Board determined the second performance milestone criteria were met

Expected evaluation timing Q1 2027 Evaluation Date anticipated for vesting, subject to continued service

Key Terms

Restricted Stock Units, Performance stock units, Performance Milestones, non-market and non-financial

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Performance stock units financial

"Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

Performance Milestones financial

"four independent performance milestones predetermined by the Board ("Performance Milestones")"

non-market and non-financial financial

"Performance Milestones are tied to the achievement of certain business objectives ... and are non-market and non-financial in nature"

Form 4 Insider Transactions: What Each Field Means →

04/21/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brooks Gabriel

(Last)

(First)

(Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN

MASSACHUSETTS

02129

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	01/29/2026		A		58,847		⁽²⁾	⁽²⁾	Common Stock	58,847	$0.00	58,847	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

2. Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

	/s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Solid Biosciences (SLDB) report for Brooks Gabriel?

Brooks Gabriel, Solid Biosciences’ Chief Medical Officer, reported an acquisition of 58,847 restricted stock units. These RSUs stem from performance stock units where the second performance milestone was certified as achieved, making this a compensation-related equity award rather than an open-market stock purchase or sale.

How many RSUs did SLDB’s Chief Medical Officer receive in this Form 4 filing?

The filing shows that Brooks Gabriel was credited with 58,847 restricted stock units. Each RSU represents a contingent right to receive one share of Solid Biosciences common stock, subject to future vesting conditions linked to continued service with the company through a specified evaluation date.

What are the performance conditions behind Solid Biosciences (SLDB) RSUs reported for Brooks Gabriel?

The RSUs arise from performance stock units granted June 11, 2024, tied to four independent performance milestones. Each milestone covers 25% of the target RSUs and is based on non-market and non-financial business objectives certified by the Board on specified evaluation dates.

When are the newly reported RSUs for SLDB’s Brooks Gabriel expected to vest?

The RSUs linked to the second performance milestone will vest only if Brooks Gabriel continues serving the company through the Evaluation Date. That Evaluation Date is anticipated to occur in the first quarter of 2027, according to the performance stock unit terms described in the footnotes.

Were Brooks Gabriel’s SLDB transactions open-market trades or equity compensation?

The reported transaction reflects equity compensation, not open-market trading. Brooks Gabriel received 58,847 restricted stock units as a grant tied to performance stock units, following the Board’s certification that the second performance milestone under the 2024 PSU grant had been achieved.

How are performance milestones structured for SLDB’s 2024 performance stock units?

The 2024 performance stock units provide for four independent performance milestones, each linked to 25% of the target RSUs. Milestones are based on non-market, non-financial business objectives, and vesting occurs only after Board certification and continued service through the applicable evaluation date.